Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, June 1, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Ed Arce Reiterated (ARCT) at Strong Buy and Held Target at $51 on, Jun 1st, 2023
Ed Arce of HC Wainwright & Co., Reiterated "Arcturus Therapeutics Holdings Inc." (ARCT) at Strong Buy and Held Target at $51 on, Jun 1st, 2023.
Ed has made no other calls on ARCT in the last 4 months.
There is 1 other peer that has a rating on ARCT. Out of the 1 peers that are also analyzing ARCT, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Seamus Fernandez of "Guggenheim" Reiterated at Strong Buy and Held Target at $36 on, Wednesday, March 29th, 2023
